NYSE:AORT Artivion (AORT) Stock Price, News & Analysis $27.48 +0.02 (+0.07%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$27.16▼$28.0350-Day Range$23.12▼$28.4652-Week Range$12.16▼$29.24Volume151,605 shsAverage Volume319,768 shsMarket Capitalization$1.15 billionP/E RatioN/ADividend YieldN/APrice Target$28.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Artivion alerts: Email Address Artivion MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside3.1% Upside$28.33 Price TargetShort InterestBearish7.87% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.34Based on 3 Articles This WeekInsider TradingSelling Shares$23,290 Sold Last QuarterProj. Earnings Growth62.50%From $0.24 to $0.39 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.73 out of 5 starsMedical Sector860th out of 936 stocksSurgical & Medical Instruments Industry92nd out of 101 stocks 1.5 Analyst's Opinion Consensus RatingArtivion has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArtivion has only been the subject of 3 research reports in the past 90 days.Read more about Artivion's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted7.87% of the float of Artivion has been sold short.Short Interest Ratio / Days to CoverArtivion has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.Change versus previous monthShort interest in Artivion has recently increased by 6.94%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArtivion does not currently pay a dividend.Dividend GrowthArtivion does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AORT. Previous Next 2.4 News and Social Media Coverage News SentimentArtivion has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Artivion this week, compared to 2 articles on an average week.Search Interest2 people have searched for AORT on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Artivion to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Artivion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,290.00 in company stock.Percentage Held by InsidersOnly 8.10% of the stock of Artivion is held by insiders.Percentage Held by Institutions86.37% of the stock of Artivion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Artivion's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Artivion are expected to grow by 62.50% in the coming year, from $0.24 to $0.39 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Artivion is -114.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Artivion is -114.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArtivion has a P/B Ratio of 4.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Artivion's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…Check out the new "Crypto Bull Run Millionaire Blueprint" now! About Artivion Stock (NYSE:AORT)Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.Read More AORT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AORT Stock News HeadlinesJuly 25 at 4:10 PM | prnewswire.comArtivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial ResultsJuly 21, 2024 | lse.co.ukArtivion Share Price (AORT.US)July 27, 2024 | Crypto 101 Media (Ad)Next opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…July 3, 2024 | investorplace.com3 Earnings All-Stars With More Room to RunJuly 1, 2024 | prnewswire.comArtivion Amends Agreements with EndospanJune 21, 2024 | seekingalpha.comData-Driven Growth Fuels More Upside For Overlooked ArtivionMay 8, 2024 | finance.yahoo.comShareholders Will Probably Hold Off On Increasing Artivion, Inc.'s (NYSE:AORT) CEO Compensation For The Time BeingMay 7, 2024 | markets.businessinsider.comArtivion: Strong Q1 Performance and Raised Guidance Validate Buy RatingJuly 27, 2024 | Crypto 101 Media (Ad)Next opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…May 7, 2024 | markets.businessinsider.comBreaking Down Artivion: 4 Analysts Share Their ViewsMay 7, 2024 | msn.comArtivion, Inc. (NYSE:AORT) Q1 2024 Earnings Call TranscriptMay 7, 2024 | finance.yahoo.comArtivion Inc (AORT) Q1 2024 Earnings Call Transcript Highlights: Strong Growth and Strategic ...May 7, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Lineage Therap (LCTX), Axonics Modulation Technologies (AXNX) and Artivion (AORT)May 7, 2024 | msn.comAORT Stock Earnings: Artivion Beats EPS, Beats Revenue for Q1 2024May 6, 2024 | uk.finance.yahoo.comArtivion Inc (AORT) Surpasses Analyst Revenue Forecasts with Strong Q1 2024 PerformanceMay 6, 2024 | prnewswire.comArtivion Reports First Quarter 2024 Financial ResultsApril 30, 2024 | msn.comAtriCure Q1 2024 Earnings PreviewApril 30, 2024 | finance.yahoo.comArtivion presents double win at AATS for aortic devicesSee More Headlines Receive AORT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artivion and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today7/27/2024Next Earnings (Confirmed)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNYSE:AORT CUSIPN/A CIK784199 Webwww.cryolife.com Phone(770) 419-3355Fax770-426-0031Employees1,500Year FoundedN/APrice Target and Rating Average Stock Price Target$28.33 High Stock Price Target$30.00 Low Stock Price Target$25.00 Potential Upside/Downside+3.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.24) Trailing P/E RatioN/A Forward P/E Ratio114.50 P/E GrowthN/ANet Income$-30,690,000.00 Net Margins-2.61% Pretax Margin0.03% Return on Equity3.64% Return on Assets1.32% Debt Debt-to-Equity Ratio1.07 Current Ratio6.04 Quick Ratio4.26 Sales & Book Value Annual Sales$354 million Price / Sales3.24 Cash Flow$0.77 per share Price / Cash Flow35.74 Book Value$6.87 per share Price / Book4.00Miscellaneous Outstanding Shares41,700,000Free Float38,322,000Market Cap$1.15 billion OptionableOptionable Beta1.75 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. James Patrick Mackin (Age 57)Chairman, President & CEO Comp: $2.37MMs. Amy D. Horton CPA (Age 54)VP & Chief Accounting Officer Comp: $621.26kMs. Jean F. Holloway Esq. (Age 67)Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $841.43kMr. John E. Davis (Age 59)Senior VP & Chief Commercial Officer Comp: $802.02kMr. Matthew A. Getz (Age 55)VP of Human Resources & Chief Human Resources Officer Dr. Marshall S. Stanton M.D. (Age 67)Senior VP of Clinical Research & Chief Medical Officer Comp: $615.55kDr. Robert C. Thomson (Age 54)Vice President of Research & Development Mr. Florian TyrsVice President of Global OperationsMore ExecutivesKey CompetitorsPROCEPT BioRoboticsNASDAQ:PRCTInari MedicalNASDAQ:NARIiRhythm TechnologiesNASDAQ:IRTCCONMEDNYSE:CNMDNovoCureNASDAQ:NVCRView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 2,018 shares on 7/26/2024Ownership: 0.724%RiverPark Advisors LLCBought 2,141 shares on 7/26/2024Ownership: 0.005%Louisiana State Employees Retirement SystemBought 600 shares on 7/24/2024Ownership: 0.048%Comerica BankSold 1,515 shares on 5/17/2024Ownership: 0.040%Tidal Investments LLCBought 12,130 shares on 5/17/2024Ownership: 0.029%View All Insider TransactionsView All Institutional Transactions AORT Stock Analysis - Frequently Asked Questions How have AORT shares performed this year? Artivion's stock was trading at $17.88 at the beginning of 2024. Since then, AORT stock has increased by 53.7% and is now trading at $27.48. View the best growth stocks for 2024 here. How were Artivion's earnings last quarter? Artivion, Inc. (NYSE:AORT) issued its quarterly earnings data on Monday, May, 6th. The company reported $0.06 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.04. The company earned $97.43 million during the quarter, compared to analysts' expectations of $92.30 million. Artivion had a negative net margin of 2.61% and a positive trailing twelve-month return on equity of 3.64%. Who are Artivion's major shareholders? Artivion's top institutional investors include Bank of New York Mellon Corp (0.72%), Louisiana State Employees Retirement System (0.05%), RiverPark Advisors LLC (0.01%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include James P Mackin, David Ashley Lee, Jean F Holloway, Marshall S Stanton, Matthew A Getz, Andrew M Green, Rochelle L Maney and Dennis B Maier. View institutional ownership trends. How do I buy shares of Artivion? Shares of AORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:AORT) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artivion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artivion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.